演題詳細

一般口演 / Oral Session

一般口演 11 (Oral Session 11) :低悪性度B細胞リンパ腫:治療研究

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
小宅 達郎 (Tatsuo Oyake):1
1:岩手医科大学 血液・腫瘍内科
 
前へ戻る

Risk factor for PFS after radioimmunotherapy by ibritumomab tiuxetan

演題番号 : OS-1-53

鵜池 直邦 (Naokuni Uike):1、安部 康信 (Yasunobu Abe):1、末廣 陽子 (Youko Suehiro):1、崔 日承 (Ilseung Choi):1、豊田 康祐 (Kosuke Toyoda):1、土師 正二郎 (Shojiro Haji):1、津田 麻理子 (Mariko Tsuda):1、古海 和博 (Kazuhiro Furumi):2、林 稔展 (Toshinobu Hayashi):2、樋口 暁 (Satoru Higuchi):2、杉 枝里香 (Erika Sugi):2、中川 誠 (Makoto Nakagawa):3、金子 恒一郎 (Kouichirou Kaneko):4

1:Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan、2:Department of a Medicine, National Kyushu Cancer Center, Fukuoka, Japan、3:Devision of Radiology, Koga Hospital 21, Kurume, Japan、4:PET Diagnostic Imaging Center, Fukuoka Central Health Evaluation and Promotion Center, Fukuoka, Japan

 

[Introduction] In order to use ibritumomab tiuxetan(Zevalin) for relapsed or refractory low-grade B cell lymphoma(rLGB) more efficiently we analyzed, retrospectively, the risk factors for progression free survival(PFS) among 90 Japanese patients(pts) in one institution(Kyusyu Cancer Center).
[Patients and Methods] From October 2008 to March 2013 we have treated just one hundred patients with rLGB, 90 pts of whom can be analyzed not only for response rate but also for PFS. Patients with pre-treatment platelet counts of >150.000/mm3 at 14.8MBq/kg whereas those with platelet count of <150.000 /mm3 received 11.1MBq/kg. Response to treatment was evaluated by 8 to 10 weeks after 90Y-ibritumomab treatment by PET/CT scan following revised IWR.
[Results] M/F 50/50, Age 64(31-90)y, stage I,II/III,IV 21/78, FL/non-FL 81/19. Median number of prior treatment regime 1(1-8). All but one had been treated with Rituximab. ORR was 90 with CR of 66%. Whether or not, CR vs non-CR, treated with under 2 or over 3 regime, FLIPI low, int or high just before Zevalin were the factors that had an effect, statistically, on PFS by the univariate analysis. No. of regime (under 2 or over 3 regime) also influenced whether a patient became CR or not. On the other hand by the multivariate analysis only whether achievement of CR or not significantly affected PFS.
[Discussion] In order to realize the best results, Most important factor is whether, after Zevalin therapy, patients achieve CR or not. We recommend that in the treatment of rLGB, Zevalin had better be used at least as the third line therapy.

前へ戻る